Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.49 |
| ▸ | MLYCD | O95822 | 2/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 8/20 | 0.38 |
| ▸ | PPARD | Q03181 | 7/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009934 | 0.90 | PTGES (0.44) | PTGESMLYCDPPARDPPARGGCK | |
| SCHEMBL3582187 | 0.85 | PTGES (0.67) | PTGESPPARAPPARDPPARGFFAR4 | |
| SCHEMBL335073 | 0.83 | PTGES (0.44) | PTGESMLYCDPLA2G4APPARAPPARD | |
| SCHEMBL3571641 | 0.82 | PTGES (0.53) | PTGESMLYCDPPARDGCK | |
| SCHEMBL335152 | 0.80 | PTGES (0.43) | PTGESPLA2G4APPARAPPARDPPARG | |
| SCHEMBL333748 | 0.78 | PTGES (0.42) | PTGESPLA2G4APPARAPPARDPPARG | |
| SCHEMBL3011271 | 0.77 | PTGES (0.45) | PTGESPPARAPPARG | |
| SCHEMBL334396 | 0.77 | PTGES (0.45) | PTGESPPARAPPARG | |
| SCHEMBL3001794 | 0.77 | PTGES (0.45) | PTGESPPARAPPARG | |
| SCHEMBL3013088 | 0.77 | PTGES (0.45) | PTGESPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | PTGES 33/4885MLYCD 1376/4885PLA2G4A 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.